Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Decreases By 70.4%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 20,390 shares, a decrease of 70.4% from the May 31st total of 68,896 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 76,356 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent SEC filing. 11.77% of the stock is owned by hedge funds and other institutional investors.

Matinas Biopharma Stock Up 3.1%

NYSEAMERICAN:MTNB traded up $0.02 during midday trading on Friday, reaching $0.64. The stock had a trading volume of 52,415 shares, compared to its average volume of 68,658. The stock has a market cap of $4.12 million, a P/E ratio of -0.32 and a beta of 1.67. Matinas Biopharma has a 12-month low of $0.48 and a 12-month high of $3.09. The firm has a fifty day simple moving average of $0.67 and a two-hundred day simple moving average of $0.64.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.